Comparing Elekta (EKTAY) & Its Competitors

Elekta (OTCMKTS: EKTAY) is one of 21 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its peers? We will compare Elekta to similar companies based on the strength of its dividends, valuation, earnings, risk, institutional ownership, analyst recommendations and profitability.

Dividends

How to Become a New Pot Stock Millionaire

Elekta pays an annual dividend of $0.08 per share and has a dividend yield of 0.7%. Elekta pays out 200.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Medical laboratories” companies pay a dividend yield of 1.9% and pay out 38.2% of their earnings in the form of a dividend. Elekta lags its peers as a dividend stock, given its lower dividend yield and higher payout ratio.

Earnings & Valuation

This table compares Elekta and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Elekta $1.23 billion $14.30 million 268.00
Elekta Competitors $1.13 billion $76.65 million 215.77

Elekta has higher revenue, but lower earnings than its peers. Elekta is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

0.0% of Elekta shares are held by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are held by institutional investors. 18.5% of shares of all “Medical laboratories” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Elekta and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elekta 0 1 0 0 2.00
Elekta Competitors 110 455 531 17 2.41

As a group, “Medical laboratories” companies have a potential upside of 16.11%. Given Elekta’s peers stronger consensus rating and higher possible upside, analysts plainly believe Elekta has less favorable growth aspects than its peers.

Risk & Volatility

Elekta has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Elekta’s peers have a beta of 1.23, suggesting that their average stock price is 23% more volatile than the S&P 500.

Profitability

This table compares Elekta and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Elekta 5.79% 9.72% 3.23%
Elekta Competitors -118.65% -181.74% -42.76%

Summary

Elekta peers beat Elekta on 10 of the 15 factors compared.

Elekta Company Profile

Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualizes tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; Monaco, a treatment planning system; Venezia, an applicator for treating gynecological cancer; and METRIQ, a cancer registry data solution. It also offers installation, implementation, training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Enable Midstream Partners LP  Expected to Post Earnings of $0.22 Per Share
Enable Midstream Partners LP Expected to Post Earnings of $0.22 Per Share
Farmer Brothers  Expected to Post Quarterly Sales of $160.95 Million
Farmer Brothers Expected to Post Quarterly Sales of $160.95 Million
Brokerages Anticipate Tanger Factory Outlet Centers  Will Post Quarterly Sales of $117.95 Million
Brokerages Anticipate Tanger Factory Outlet Centers Will Post Quarterly Sales of $117.95 Million
Barclays Reaffirms Hold Rating for Webster Bank
Barclays Reaffirms Hold Rating for Webster Bank
Gazit Globe  and Getty Realty  Head to Head Survey
Gazit Globe and Getty Realty Head to Head Survey
RTI Surgical  & Coloplast  Critical Contrast
RTI Surgical & Coloplast Critical Contrast


Leave a Reply

© 2006-2018 Ticker Report. Google+.